Related Experiment Video

Updated: Sep 21, 2025

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.7K

Natural Compound Library Screening Identifies Oroxin A for the Treatment of Myocardial Ischemia/Reperfusion Injury

Xingdong Cheng1,2, Tingting Huang1, Chunhui Wang1

  • 1Department of Anesthesiology, The Forth Affiliated Hospital of Anhui Medical University, Hefei, China.

Frontiers in Pharmacology
|June 1, 2022
PubMed

Insights

Oroxin A (OA) effectively reduces inflammation and pyroptosis in myocardial ischemia/reperfusion injury (MI/RI). This natural compound improves cardiac function and may offer a novel therapeutic strategy for cardiovascular disease treatment.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Cellular Biology

Background:

  • Myocardial ischemia/reperfusion injury (MI/RI) is a critical complication of cardiovascular disease.
  • Oroxin A (OA), a natural flavonoid glycoside, possesses diverse biological activities.
  • The therapeutic potential of OA in MI/RI remains unexplored.

Purpose of the Study:

  • To investigate the protective effects of Oroxin A against MI/RI.
  • To determine if OA can alleviate inflammation and pyroptosis in MI/RI.
  • To explore OA as a potential therapeutic agent for MI/RI.

Main Methods:

  • High-throughput screening of natural compounds.
  • Establishment of a rat model for MI/RI (coronary artery ligation).
  • In vitro simulation of MI/RI using H9c2 cells (oxygen-glucose deprivation/reperfusion).

Main Results:

  • Oroxin A significantly inhibited apoptosis, pyroptosis, and inflammatory responses (e.g., TNF-α, IL-6, IL-1β) in vivo and in vitro.
  • OA reduced the release of key myocardial enzymes (cTnI, cTnT, CK-MB, LDH, AST).
  • In the rat model, OA improved cardiac function, reduced inflammatory cell infiltration, and decreased infarct size.

Conclusions:

  • Oroxin A demonstrates significant efficacy in mitigating MI/RI.
  • OA's mechanism involves reducing inflammation and inhibiting pyroptosis.
  • OA presents a promising therapeutic target for clinical management of MI/RI.
Keywords:
high-throughput drug screeningmyocardial ischemia/reperfusion injuryoroxin Aoxygen-glucose deprivation/reperfusionpyroptosis

More Related Videos

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

6.3K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.0K

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
751
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
775
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
37
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
27
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
715
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.9K